search
Back to results

Mediterranean-style Dietary Pattern (MDP), Mood and Anxiety (MediMood)

Primary Purpose

Depression, Anxiety

Status
Recruiting
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Mediterranean diet
Western diet
Sponsored by
University of East Anglia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Depression, Anxiety

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Male and female, aged 18 or above Is willing and able to comply with all study procedures, including changes in diets Has access to and able to use the internet/computer/tablet device Mild to moderate level of anxiety and/or depression symptoms, assessed by Generalised Anxiety disorder (GAD-7) score and Patient Health Questionnaire (PHQ-9), scores 5 to 14 on both questionnaires A habitual MEDAS score of ≤ 7/14 To be fluent in English Exclusion Criteria: MEDAS score >7 Vegan/vegetarian Allergies to one of the study components i.e. nuts, fish On antidepressant or antianxiety medication where dosage is likely to change over the next 3 month Factors precluding MRI scanning such as suffers from claustrophobia or has metal implants Not fluent in English Not agreement for the study team to contact the participants general practitioner about trial participation and screening results Not prepared to make changes to the diet for 10 days (2 x 5 day periods)

Sites / Locations

  • University of East AngliaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Mediterranean-style dietary pattern

Western-style dietary pattern

Arm Description

A Mediterranean-style diet (as a whole diet, no supplements)

A Western-style diet (as a whole diet, no supplements)

Outcomes

Primary Outcome Measures

Change in mood
Established by the Bond-Lader visual analogue scale (includes 16 items each having antonyms on two ends, on a scale of 1 to 100, 50 being the neutral point)
Change in anxiety
Established by the Profile of Mood States (includes 65 items on a 5 point Likert scale)

Secondary Outcome Measures

Change in cognitive performance
Established by a neuropsychological test battery (https://neuropsychology.online) which assesses the following measures; attention, motor function, executive function, episodic memory, impulse control, visuospatial function
Cerebral blood flow
Measured using MRI
Change in blood pressure
Measurements of brachial artery blood pressure (both diastolic and systolic pressure)
Change in gut microbiota speciation
Faecal samples will be analysed for the gut microflora using 16sRNA sequencing.
Change in plasma short chain fatty acids (SCFA)
Acetate, propionate and butyrate
Change in untargeted metabolomics
Analysed through faecal samples using 1H-NMR-based untargeted metabolomics approach.
Habitual sleep quality profile assessed by the Pittsburgh Sleep Quality Index
The Pittsburgh Sleep Quality Index is a 10-items validated questionnaire, which is based on 'the last month'. It will be used to establish usual sleep habits (before the interventions) and to identify sleep disturbances if there is any.
Change in subjective sleep quantity
Assessed using the Karolinska Sleep Diary (KSD). The KSD is a series of questions, with 5 possible tick box options, which characterise the efficiency and the duration of last night's sleep.
Change in subjective sleep quality
Assessed using the Karolinska Sleepiness Scale (KSS). The KSS is a single item, 9-point scale, assessing the sleepiness level at a particular time of day.
Change in objective sleep quality
Assessed using the MotionWatch 8. The MotionWatch 8 is a medical-grade actigraphy watch which can be used to monitor sleep, circadian rhythm and physical activity. Its software (The Motion Ware) will provide two objective measures of sleep quality, namely sleep efficiency and sleep fragmentation.
APOE4 genotype status
Assessed through DNA genotyping
Participants subjective overview of the intervention
Assessed through a non-validated single question

Full Information

First Posted
March 2, 2023
Last Updated
June 27, 2023
Sponsor
University of East Anglia
Collaborators
Newcastle University
search

1. Study Identification

Unique Protocol Identification Number
NCT05927376
Brief Title
Mediterranean-style Dietary Pattern (MDP), Mood and Anxiety
Acronym
MediMood
Official Title
MediMood: A Randomised Controlled Trial Investigating the Acute Impact of a Plant Based Mediterranean-style Dietary Pattern (MDP) on Mood, Anxiety and Cognition in UK Adults With Mild to Moderate Mental Health Complaints
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 14, 2023 (Anticipated)
Primary Completion Date
June 30, 2024 (Anticipated)
Study Completion Date
June 30, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of East Anglia
Collaborators
Newcastle University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Observational studies and a limited numbers of RCTs have observed that habitual Mediterranean-style dietary pattern (MDP) consumption is associated with improved mental health and cognition. Yet, its efficacy in a short-term has not been studied in well-controlled intervention settings. MediMood is a cross-over RCT aiming to test whether a MDP can affect mood and anxiety following a meal (postprandial) and over 5-days in adults over 18 years with mild to moderate mental health problems relative to a Western diet (WD).
Detailed Description
Depression, anxiety and age-related cognitive decline are leading global public health problems. A plant-based Mediterranean-style dietary pattern (MDP) includes olive oil as the main source of fat, fresh fruits, vegetables, seafood, legumes and nuts and a low consumption of red and processed meat, confectionary, and high-sugar drinks. A MDP promotes both physical and mental wellbeing and brain function. However, most studies to date have examined the impact of a MDP on health over months or years. As several underpinning biological mechanisms are likely to be responsive within hours or days, examining the short-term effect of a MDP on mental health outcomes is important. The overall goal of the present study is to understand the effects of a MDP on acute/sub-chronic brain health and its underpinning mechanisms. MediMood is a randomised cross-over efficacy trial. Participants will be assigned to an isocaloric MDP and a Western diet (WD) for 5-days in a random order with a 4-week wash-out period. All foods, meal plans and detailed dietary instructions will be provided. In addition to the primary outcome measures (mood and anxiety), the impact of intervention on cognitive performance, sleep, cerebral blood flow (MRI) and a selection of biomarkers of brain function will be measured in biological samples over five days. As low mood, anxiety and stress disorders affect daily functioning and reduce the quality of life significantly for many, the investigators believe the findings will have wide public health application.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression, Anxiety

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
25 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Mediterranean-style dietary pattern
Arm Type
Experimental
Arm Description
A Mediterranean-style diet (as a whole diet, no supplements)
Arm Title
Western-style dietary pattern
Arm Type
Active Comparator
Arm Description
A Western-style diet (as a whole diet, no supplements)
Intervention Type
Behavioral
Intervention Name(s)
Mediterranean diet
Intervention Description
All foods, meal plans and instructions provided.
Intervention Type
Behavioral
Intervention Name(s)
Western diet
Intervention Description
All foods, meal plans and instructions provided.
Primary Outcome Measure Information:
Title
Change in mood
Description
Established by the Bond-Lader visual analogue scale (includes 16 items each having antonyms on two ends, on a scale of 1 to 100, 50 being the neutral point)
Time Frame
Baseline (morning of day 1), Postprandial (after lunch on Established by the Bond-Lader visual analogue scale (includes 16 items each having day 1), 24-hours (morning of day 2), day 5 (morning of day 6 upon completion of 5 full days intervention)
Title
Change in anxiety
Description
Established by the Profile of Mood States (includes 65 items on a 5 point Likert scale)
Time Frame
Baseline (morning of day 1), Postprandial (after lunch on day 1), 24-hours (morning of day 2), day 5 (morning of day 6 upon completion of 5 full days intervention)
Secondary Outcome Measure Information:
Title
Change in cognitive performance
Description
Established by a neuropsychological test battery (https://neuropsychology.online) which assesses the following measures; attention, motor function, executive function, episodic memory, impulse control, visuospatial function
Time Frame
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
Title
Cerebral blood flow
Description
Measured using MRI
Time Frame
Postprandial day 1
Title
Change in blood pressure
Description
Measurements of brachial artery blood pressure (both diastolic and systolic pressure)
Time Frame
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
Title
Change in gut microbiota speciation
Description
Faecal samples will be analysed for the gut microflora using 16sRNA sequencing.
Time Frame
Baseline (morning of day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
Title
Change in plasma short chain fatty acids (SCFA)
Description
Acetate, propionate and butyrate
Time Frame
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
Title
Change in untargeted metabolomics
Description
Analysed through faecal samples using 1H-NMR-based untargeted metabolomics approach.
Time Frame
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
Title
Habitual sleep quality profile assessed by the Pittsburgh Sleep Quality Index
Description
The Pittsburgh Sleep Quality Index is a 10-items validated questionnaire, which is based on 'the last month'. It will be used to establish usual sleep habits (before the interventions) and to identify sleep disturbances if there is any.
Time Frame
Baseline (morning of day 1)
Title
Change in subjective sleep quantity
Description
Assessed using the Karolinska Sleep Diary (KSD). The KSD is a series of questions, with 5 possible tick box options, which characterise the efficiency and the duration of last night's sleep.
Time Frame
Each morning, days 1-6
Title
Change in subjective sleep quality
Description
Assessed using the Karolinska Sleepiness Scale (KSS). The KSS is a single item, 9-point scale, assessing the sleepiness level at a particular time of day.
Time Frame
Each morning, days 1-6
Title
Change in objective sleep quality
Description
Assessed using the MotionWatch 8. The MotionWatch 8 is a medical-grade actigraphy watch which can be used to monitor sleep, circadian rhythm and physical activity. Its software (The Motion Ware) will provide two objective measures of sleep quality, namely sleep efficiency and sleep fragmentation.
Time Frame
Each morning, days 1-6
Title
APOE4 genotype status
Description
Assessed through DNA genotyping
Time Frame
Baseline (day 1)
Title
Participants subjective overview of the intervention
Description
Assessed through a non-validated single question
Time Frame
Upon completion of 5 full days
Other Pre-specified Outcome Measures:
Title
Change in dietary behaviour
Description
Through the Mediterranean Diet Adherence Screener (14 items food questionnaire, MEDAS) questionnaire, with a minimum score of 0 and a maximum of 14. A higher score indicates a higher diet quality which is a better outcome
Time Frame
Screening and 3 months upon the completion
Title
Change in plasma insulin
Description
Measured using ELISA
Time Frame
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
Title
Change in plasma glucose
Description
Measured by autoanalyser
Time Frame
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
Title
Change in plasma triglycerides
Description
Measured by autoanalyser
Time Frame
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
Title
Change in plasma cortisol
Description
Measured by autoanalyser
Time Frame
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
Title
Change in plasma brain derived neurotropic factor
Description
Measured by ELISA
Time Frame
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
Title
Change in plasma serotonin
Description
Measured by ELISA
Time Frame
Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male and female, aged 18 or above Is willing and able to comply with all study procedures, including changes in diets Has access to and able to use the internet/computer/tablet device Mild to moderate level of anxiety and/or depression symptoms, assessed by Generalised Anxiety disorder (GAD-7) score and Patient Health Questionnaire (PHQ-9), scores 5 to 14 on both questionnaires A habitual MEDAS score of ≤ 7/14 To be fluent in English Exclusion Criteria: MEDAS score >7 Vegan/vegetarian Allergies to one of the study components i.e. nuts, fish On antidepressant or antianxiety medication where dosage is likely to change over the next 3 month Factors precluding MRI scanning such as suffers from claustrophobia or has metal implants Not fluent in English Not agreement for the study team to contact the participants general practitioner about trial participation and screening results Not prepared to make changes to the diet for 10 days (2 x 5 day periods)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Anne Marie M Minihane, PhD
Phone
01603592389
Email
a.minihane@uea.ac.uk
First Name & Middle Initial & Last Name or Official Title & Degree
Latife Esgunoglu, MSc
Phone
+441603592389
Email
l.esgunoglu@uea.ac.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anne Marie Minihane
Organizational Affiliation
University of East Anglia
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of East Anglia
City
Norwich
State/Province
Norfolk
ZIP/Postal Code
NR4 7UQ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Latife Esgunoglu, MSc
Phone
+441603592389
Email
l.esgunoglu@uea.ac.uk
First Name & Middle Initial & Last Name & Degree
Anne Marie Minihane, PhD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Mediterranean-style Dietary Pattern (MDP), Mood and Anxiety

We'll reach out to this number within 24 hrs